Amicus Therapeutics — Corporate Update (May 2019)
14 slides from Amicus Therapeutics's corporate update, May 29, 2019
Slide 1: Amicus Therapeutics Expands Gene Therapy Collaboration with University of Pennsylvania
Amicus Therapeutics Expands Gene Therapy Collaboration with University of Pennsylvania May 29, 2019
Slide 2: Forward-Looking Statements
Expansion of Amicus and Penn Gene Therapy Collaboration 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timi
Slide 3: Amicus Gene Therapy Expansion Transforms Amicus into a True Platform Gene Therapy Company
Expansion of Amicus and Penn Gene Therapy Collaboration 3 Amicus Gene Therapy Expansion Transforms Amicus into a True Platform Gene Therapy and Protein Engineering Company at the Forefront of Human Genomic Medicine with Industry Leading Gene Therapy Pipeline in Rare Diseases Partnership Combines Ami
Slide 4: Expanded Amicus-Penn Collaboration Terms
Expansion of Amicus and Penn Gene Therapy Collaboration 4 Expanded Amicus-Penn Collaboration Terms World Class Industry-Academia Partnership in Rare Diseases Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysoso
Slide 5: Amicus Global Research and Gene Therapy Center of Excellence in Philadelphia
Expansion of Amicus and Penn Gene Therapy Collaboration 5 Amicus Global Research and Gene Therapy Center of Excellence in Philadelphia Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company in Burgeoning Hub for Medical Breakthroughs » New 75,000 sqft state-of-the-art
Slide 6: Amicus Protein Engineering Expertise & Technologies for Gene Therapy
Expansion of Amicus and Penn Gene Therapy Collaboration 6 Amicus Protein Engineering Expertise & Technologies for Gene Therapy Collaboration to Enable Greater Protein Expression and Delivery at Lower Gene Therapy Doses Increased Increased Improved Protein Protein Protein Targeting & Stabilization Ex
Slide 7: MPS IIIB Disease Overview
Expansion of Amicus and Penn Gene Therapy Collaboration 7 MPS IIIB Disease Overview Fatal Lysosomal Disorder with Progressive Clinical Manifestations in Central Nervous System (CNS) and Spinal Cord • Mutation of alpha-N-acetylglucosaminidase (NAGLU) leads to accumulation of glycoaminoglycans (GAGs)
Slide 8: MPS IIIB Program Summary
Expansion of Amicus and Penn Gene Therapy Collaboration 8 MPS IIIB Program Summary MPS IIIB program will Assess Whether Existing AAV-NAGLU Candidate can be Further Improved to Enhance Cellular Uptake and Cross-Correction of Affected Cells AAV-NAGLU Candidate (Unmodified WT): KO Mouse* NAGLU Binding
Slide 9: Rare Disease Pipeline Franchises
Expansion of Amicus and Penn Gene Therapy Collaboration 9 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies C
Slide 10: Rare Disease Operational Excellence
Expansion of Amicus and Penn Gene Therapy Collaboration 10 Rare Disease Operational Excellence Proven Capabilities Position Amicus at the Forefront of Human Genomic Medicine to Develop and Deliver the Highest Quality Therapies and Cures for Persons Living with Rare Diseases 5 Key Pillars of Value In
Slide 11: Anticipated Milestones: 2019
Expansion of Amicus and Penn Gene Therapy Collaboration 11 Anticipated Milestones: 2019 Well-Positioned to Create Significant Value for Patients and Shareholders in 2019 Galafold: Fabry Disease AT-GAA: Pompe Disease Gene Therapy Programs • FY19 revenue guidance $160M- Additional Phase 1/2 data (21
Slide 12: Impacting Lives
Expansion of Amicus and Penn Gene Therapy Collaboration 12 Impacting Lives >350 Patients* | ~$36M Global Sales >700 Patients* | ~$91M1 Global Sales 5,000 Patients* | $1B Global Sales YE17 YE18 2023 *Clinical & commercial, all figures approximate 1Preliminary unaudited
Slide 13: A Leader in the Human Genome Medicine Revolution
Expansion of Amicus and Penn Gene Therapy Collaboration 13 A Leader in the Human Genome Medicine Revolution 5,000 Patients* $1B Global Sales MORE Patients More Indications 2023 LONGER - TERM VISION *Clinical & commercial, all figures approximate 1Preliminary unaudited
Slide 14: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement